Vaccine News and Research

Latest Vaccine News and Research

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Geron Corporation announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.

30 Jul 2010

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Cancer Research UK's Drug Development Office marks the launch of its Biotherapeutics Development Unit (BDU) today (Friday) with the manufacture of its first product - an antibody for treating a range of cancers.

30 Jul 2010

Chemical compound provides new angle for developing drugs to treat seizures: Study

A chemical compound that boosts the action of a molecule normally produced in the brain may provide the starting point for a new line of therapies for the treatment of epileptic seizures, according to a new study by scientists at The Scripps Research Institute.

30 Jul 2010

Polio cases in India lowest in a decade; Vaccination effort begins in Afghanistan

This year "India has reported the lowest number of polio cases in [the] January-June period ... in a decade," PTI/ZeeTV reports. Twenty-four cases were detected between January and June this year, compared to 151 in the corresponding 2009 period, and 317 in January-June 2008 (7/29).

30 Jul 2010

PPD expands cGMP laboratory testing services into Wayne

PPD, Inc. today announced it has expanded its cGMP laboratory testing services into Wayne, Pa., to meet growing client demand for these services from pharmaceutical and biotechnology companies located in the northeastern United States.

30 Jul 2010

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

Media outlets continued to reflect on news from the International AIDS Conference-AIDS 2010, which attracted over 19,000 participants from 197 countries to Vienna last week, according to the conference blog.

30 Jul 2010

Random vaccine distribution prevents spread of disease: Study

The best way to prevent the spread of disease in rural areas may be by targeting select popular hangouts, according to a new study by the Kansas State University EpiCenter research team.The team published "Efficient Mitigation Strategies for Epidemics in Rural Regions" in the July edition of the journal PLoS ONE. The study looks at mitigation strategies based on a contact network model developed using information collected from residents in Clay County, Kan.

30 Jul 2010

Geron second-quarter net loss decreases to $17.0 million

Geron Corporation today reported financial results for the three and six months ended June 30, 2010.

30 Jul 2010

Talecris Biotherapeutics Holdings second-quarter 2010 net revenue increases 7.3% to $402.8 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and six months ended June 30, 2010 and filed its 2010 Form 10-Q with the U.S. Securities and Exchange Commission.

29 Jul 2010

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics Inc. reported today its results for the quarter ended June 30, 2010.

29 Jul 2010

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.

29 Jul 2010

Champions Biotechnology fiscal 2010 operating revenues increase to $4.89 million

Champions Biotechnology, Inc., a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2010.

29 Jul 2010

Etubics enters Phase I trials for next generation vector vaccines

Etubics Corporation, a biopharmaceutical company developing next generation vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S. Food and Drug Administration for its Investigational New Drug application to begin studying ETBX-011 in humans.

29 Jul 2010

BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award

Frost & Sullivan is pleased to announce the award of its prestigious 2010 European Influenza Vaccines Technology Innovation Award to BiondVax Pharmaceuticals for their breakthrough work on a universal influenza vaccine. This vaccine, the Multimeric-001, is designed to provide multi-season and multi-strain protection against most influenza virus strains, including both seasonal and pandemic strains, and has the potential to eliminate the need for annual flu vaccination. BiondVax is entering Phase II clinical trials for the development of the Multimeric-001 universal influenza vaccine.

28 Jul 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck announced a non-exclusive license agreement with Laboratory Corporation of America Holdings for the commercialization of a genetic test that may help predict the response of patients with Hepatitis C virus infection to peginterferon alpha-based therapy.

28 Jul 2010

Dengue fever emerges as major health threat in Gulf coast cities

Several cases of dengue fever, a potentially fatal viral disease transmitted by the bite of urban dwelling Aedes aegypti and Aedes albopictus mosquitoes, have recently been reported in the continental United States. Prevalent in Central America and the Caribbean, dengue fever's most common symptoms include fever, chills, headache, and body aches lasting several days. The disease's more threatening form, dengue hemorrhagic fever, can cause internal bleeding, loss of blood pressure, and death. Over the past five years, outbreaks of both forms of the disease have been reported in Texas and Florida.

28 Jul 2010

Merck, Sinopharm sign statement of mutual intent for cooperation on HPV vaccine

Merck, known outside the U.S. and Canada as MSD, and Sinopharm today announced the signing of a statement of mutual intent. Under the statement, Sinopharm and Merck will cooperate on HPV vaccine and other mutually-selected vaccine products in China, and will also discuss the potential for promoting and marketing Merck's pharmaceutical products in China.

28 Jul 2010

Antigenics announces positive results of AG-707 genital herpes vaccine

Antigenics announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2,the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells.

28 Jul 2010

Research on method to open blood-brain barrier for safe cancer drug delivery

One of the human body's most powerful defensive tools, the blood-brain barrier is a chemical labyrinth that prevents toxins and viruses in the bloodstream from reaching the brain. This foolproof security system, however, limits the ability of physicians to deliver drugs directly to the brain, making it difficult to treat brain tumors. Researchers at Rensselaer Polytechnic Institute are endeavoring to solve this problem by investigating new methods for bypassing the blood-brain barrier and combating the spread of brain cancer.

28 Jul 2010

VillageReach announces $5.6M program to strengthen national health system in Mozambique

VillageReach, the Seattle-based social enterprise that increases access to healthcare for remote, last mile communities in low-income countries, today announced a $5.6 million program to strengthen the national health system in Mozambique. Contributions for the six-year program total $1.2 million to date.

27 Jul 2010

Vaccine News and Research

Latest Vaccine News and Research

FDA lifts hold, allows Geron to proceed with Phase I clinical trial of GRNOPC1 in spinal cord injury

Cancer Research UK launches new £18 million Biotherapeutics Development Unit

Chemical compound provides new angle for developing drugs to treat seizures: Study

Polio cases in India lowest in a decade; Vaccination effort begins in Afghanistan

PPD expands cGMP laboratory testing services into Wayne

AIDS 2010 follow-up coverage: Global HIV/AIDS funding; HIV/AIDS studies, releases

Random vaccine distribution prevents spread of disease: Study

Geron second-quarter net loss decreases to $17.0 million

Talecris Biotherapeutics Holdings second-quarter 2010 net revenue increases 7.3% to $402.8 million

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Champions Biotechnology fiscal 2010 operating revenues increase to $4.89 million

Etubics enters Phase I trials for next generation vector vaccines

BiondVax receives 2010 European Influenza Vaccines Technology Innovation Award

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Dengue fever emerges as major health threat in Gulf coast cities

Merck, Sinopharm sign statement of mutual intent for cooperation on HPV vaccine

Antigenics announces positive results of AG-707 genital herpes vaccine

Research on method to open blood-brain barrier for safe cancer drug delivery

VillageReach announces $5.6M program to strengthen national health system in Mozambique

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in